如果用一个词语来形容2025年乳腺癌治疗领域的发展，那就是全面开花。 从新药密集上市到临床突破频频，再到积极探索新靶点与新机制，乳腺癌治疗领域可谓迎来了大爆发。 01 阿斯利康/第一三共的HER2 ADC德曲妥珠单抗（Enhertu，T-DXd）捷报频传：1月，获FDA批准上市，用于HR+/HER2低表达晚期乳腺癌的二线治疗，前移 了治疗线数；12月，获FDA批准联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗，以中位PFS突破40个月、较标准方案显著延 长并降低疾病进展或死亡风险44%的优异疗效，巩固其作为重磅炸弹药物的市场统治力。 阿斯利康与第一三共联合开发的德达博妥单抗（Dato-DXd）也是高歌猛进，先是在1月获FDA批准用于HR阳性HER2阴性乳腺癌患者的二线治疗，之后在6 月拿下第2项适应症，成为全球首个获FDA批准的针对经治晚期EGFR突变非小细胞肺癌患者的TROP2靶向疗法。 4月，阿斯利康的卡匹色替片（Capivasertib）成为首个且唯一在中国获批用于PIK3CA/AKT1/PTEN改变的乳腺癌患者的AKT抑制剂，并且突破了传统治疗 的耐药瓶颈，为乳腺癌患者提供了新 ...

Core Viewpoint - HaiChuang Pharmaceutical (688302) has made significant progress in commercialization, medical insurance access, and research pipeline, with revenue growth and reduced losses as indicated in its performance forecast [1] Group 1: Project Advancement - The company announced on February 1, 2026, that its soft capsule production line for the anti-tumor drug has passed GMP compliance inspection, indicating the core product, Deuteroenzalutamide soft capsules, is now capable of large-scale production, completing the "R&D - Production - Sales" full industry chain [2] Group 2: Business Progress - Deuteroenzalutamide soft capsules were included in the national medical insurance catalog on December 2025, effective from January 1, 2026, which is expected to enhance patient accessibility through a "direct sales + agency" dual-track model; the product was previously approved for market launch in May 2025 and included in the CSCO Prostate Cancer Diagnosis and Treatment Guidelines [3] Group 3: Product Development Progress - The company is focusing on prostate cancer and metabolic diseases, with the oral AR PROTAC drug HP518 having completed Phase I clinical trials, while Phase II trials in China and combination therapy studies are ongoing; HP515, aimed at treating metabolic-associated fatty liver disease (MASH), has entered Phase II clinical trials, with preclinical data on its combination with GLP-1 presented at international conferences [4] Group 4: Performance and Operations - The 2025 performance forecast indicates the company expects revenue between 19 million and 22 million, representing a significant year-on-year increase, with losses narrowing by 24.81% to 37.34%, primarily due to the sales of Deuteroenzalutamide [5] Group 5: Institutional Research - In January 2026, the company hosted a research meeting with 29 institutions, including Foresight Investment and Western Securities, reflecting market interest in its innovative drug pipeline [6]

2025年1-12月，四川省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为20049 个，和上年同期相比，增加了909个，同比增长4.75%，占全国的比重为3.81%。 2016-2025年四川省工业企业数统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国城矿业（000688），德龙汇能（000593），ST升达（002259），成都燃气（603053）， 金石亚药（300434），达威股份（300535），侨源股份（301286），圣诺生物（688117），海创药业 （688302），大西洋（600558），秦川物联（688528），优机股份（833943），中寰股份（836260）佳 缘科技（301117），川能动力（00015 ...

2月8日，信达生物与礼来达成合作，共同推进肿瘤及免疫领域创新药全球研发，信达生物将获3.5亿美 元首付款及最高约85亿美元里程碑付款及销售分成。 无独有偶，2月5日，复宏汉霖与日本卫材签订协议，授予其在日本区域内斯鲁利单抗注射液用于肿瘤适 应症治疗的开发、生产及商业化权利，交易总金额近4亿美元。 回顾2025年，中国创新药对外授权（License-out）交易总金额突破1300亿美元，中国医药企业的国际化 进程已逐步成为行业当前发展的主旋律。然而，在推动企业"走出去"的实践中，呈现出显著的分层特征 与结构性不均衡。一方面，以华润医药、百济神州、复星医药等为代表的龙头企业已具备较为扎实的国 际化基础；另一方面，大量中小企业则因国内市场竞争高度内卷及集采带来的经营压力，将海外市场视 为新的生存机会与发展路径。 突破核心瓶颈 合规能力是国际化的核心前提。对于原料药、中间体企业而言，过去凭借成本与产能优势尚可维持出 口，但若要进入生物医药、高端医疗器械乃至医保报销体系，则必须满足ICH、PIC/S、FDA、EMA等 国际通行的法规与质量标准。值得肯定的是，中国已正式加入ICH，并正在积极申请加入PIC/S。后者 一旦 ...

同泰大健康主题混合基金共经历4位基金经理的陆续管理，其现任基金经理为马毅和麦健沛，但可惜的 是，至今还没有一位在管理任期内实现正回报。 基金经理变动一览 中国经济网北京2月9日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟 出在哪？》一文。文中称，2021年大量主动权益基金密集成立，但2021年那一批在牛市尾声发车的基金却 并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续的667只主动权益基金为样本统计发现，截至最 新净值，仍有约362只成立以来收益为负，占比超过五成。其中86只基金自成立以来跌幅在30%以上，34只 的回撤更是超过40%。 根据天天基金网最新数据显示，成立于2021年4月8日的同泰大健康主题混合基金A/C，在截至2026年2 月6日的最新累计收益率为-56.45%和-57.28%，累计单位净值仅有0.4355元、0.4272元。 | 同泰大健康主题混合A(011002) | | | | --- | --- | --- | | 单位净值(2026-02-06) | 累计净值 | | | 0.4355 -1.34% | 0.4355 | | | 沂1月: ...

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors needing to consider the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry will rely more on key data releases, actual transactions, and visibility on earnings realization or turning points [1] Group 2: Sector Insights - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Junshi Biosciences, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector is maintained with a neutral outlook, indicating that while the industry has bottomed out, recovery will take time [1] - Recommended stocks include Angelalign Technology and Weigao Group [1]

Core Viewpoint - The article highlights the active role of Taikang Life as a cornerstone investor in the Hong Kong IPO market, particularly in sectors like AI, hard technology, biomedicine, and new consumption, indicating a strategic approach to long-term investment rather than opportunistic trading [2][10][12]. Investment Strategy - Taikang Life has participated in seven Hong Kong IPO projects since the beginning of 2026, securing nearly 1 billion HKD in allocations, showcasing its status as the most active insurer in the current market [2][10]. - The company employs a systematic investment strategy that includes cornerstone investments, strategic placements, and secondary market acquisitions, focusing on companies with established industry positions and clear growth paths [3][11][12]. Market Context - The overall insurance sector has shown a marginal shift towards IPOs and equity assets since 2025, driven by a low-interest-rate environment that compresses fixed-income returns, prompting insurers to seek new yield sources [13][14]. - Despite increased participation in IPOs, many insurers remain cautious, with Taikang Life distinguishing itself through a more consistent and strategic approach to investment [13][15]. Leadership Influence - The investment philosophy of Taikang Life is heavily influenced by its founder, Chen Dongsheng, who emphasizes long-term commitment and strategic foresight, having built the company in sectors that promise sustained growth [5][8][9]. Long-term Focus - Taikang Life's investments are not merely opportunistic but are aligned with its long-term liabilities, focusing on sectors that can provide stable returns over extended periods, such as hard technology and healthcare [12][15]. - The company has developed a comprehensive ecosystem around its insurance business, integrating healthcare and wellness services, which enhances its investment strategy and aligns with its long-term goals [9][12]. Conclusion - Taikang Life's proactive stance in the IPO market reflects a well-thought-out strategy that balances risk and return, positioning it as a model for other insurers navigating similar market conditions [16][17].

Group 1 - The recent personnel changes at Xuchang Electric have led to the election of Ji Kan as the chairman of the board, with a term lasting until the board's term ends, and he will also act as the general manager during the vacancy [1] - The previous chairman, Li Juntao, resigned on January 20 due to work adjustments, following the resignation of general manager Xu Tao on January 14 [1] - Ji Kan, born in May 1969, has extensive experience in the State Grid system and has held various leadership positions in related companies before becoming the chairman of Xuchang Electric [1][2] Group 2 - The China Electric Equipment Group has seen frequent executive changes across its seven listed companies, including the resignation of Zhang Wenbing, the general manager of Xi'an High Voltage Electric Research Institute, on January 30 [5] - Following Zhang's resignation, the chairman Zhang Jinbo will temporarily assume the role of general manager [6] - The group has experienced a significant turnover in leadership, with notable examples including the rise of Zhang Fan, born in December 1981, to a vice president position, making him one of the few post-80s individuals in such roles within state-owned enterprises [6][7] Group 3 - The recent personnel changes have affected nearly all listed companies under the China Electric Equipment Group, indicating a broader trend of restructuring within the organization [7] - The demand for transformers and power transmission equipment has surged, with the total export value of transformers in China reaching 64.6 billion yuan in 2025, a year-on-year increase of 36% [7]

Summary of the Conference Call for Fosun International Industry and Company Overview - **Company**: Fosun International - **Industry**: Diversified Holdings including healthcare, consumer products, tourism, and insurance Key Points and Arguments 1. **Strategic Focus**: Fosun International is implementing a "slimming down" strategy aimed at systematically enhancing profitability, cash flow generation, and balance sheet health over the next five years, with a gradual increase in shareholder dividends currently maintained at around 20% [2][3][4] 2. **Core Subsidiaries**: The four core subsidiaries of Fosun International are: - **Fosun Health**: Rapid growth in innovative drug revenues with multiple products showing significant potential - **Yuyuan**: Strengthened profitability in fashion jewelry and potential recovery in the liquor business due to consumer recovery - **Fosun Tourism**: Accelerating global resort network expansion with expected profitability improvements - **Fosun Insurance**: Strong premium income growth, leading market share in Portugal [4][6] 3. **Debt Management**: The company aims to reduce interest-bearing debt from a historical peak of 120 billion RMB to below 60 billion RMB, with a target for public market debt to be below 25% [2][8][10] 4. **International Market Performance**: Fosun Pharma has ten products approved in international markets, with strong sales performance and expected significant growth over the next three years, particularly in innovative products like PD-L1 and ADC [5][6] 5. **Yuyuan's Business Transformation**: Yuyuan is actively transforming its brand image and focusing on younger demographics, with new product lines and marketing strategies to align with current consumer trends [2][8] 6. **Capital Allocation**: The company prioritizes capital allocation towards four main industries: health (Fosun Pharma), consumer (Yuyuan and Fosun Tourism), wealth (Portuguese insurance), and manufacturing (Hainan Mining) [4][10] 7. **Operational Efficiency**: The management emphasizes improving operational efficiency and reducing costs, particularly in response to declining profitability in some Yuyuan segments [10][11] 8. **Future Growth Drivers**: Expected growth from innovative drug commercialization, new village expansions, and high-end tourism models is anticipated to contribute to revenue and profit from 2026 to 2027 [11] Other Important Insights - **Market Expansion**: HR Company's gastric cancer surgery phase 3 registration has been successful, with commercialization in over 30 countries, and the U.S. market approval will follow local clinical approval timelines [7] - **IPO Plans**: Fosun Pharma is initiating A-share IPO guidance, which may enhance the valuation of its assets and the overall group [9] - **Collaboration with Clavis Bio**: Fosun Pharma's collaboration involves shared development responsibilities, with specific details to be disclosed publicly [9] This summary encapsulates the essential insights from the conference call, highlighting the strategic direction, financial health, and growth prospects of Fosun International and its subsidiaries.

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...